Cardarine

Cardarine (GW501516) is a high-affinity, selective agonist of peroxisome proliferator-activated receptor delta (PPARδ) — a nuclear receptor that sits at the center of how skeletal muscle and liver decide whether to burn fat or store it. It is not a SARM in the mechanistic sense: it does not bind the androgen receptor, does not aromatize, does not suppress the HPTA, and is not anabolic. What it does is transcriptionally reprogram your tissues toward fatty-acid oxidation, and that reprogramming is what drives the effortless-cardio and conditioning effects users show up for.

PPARδ Activation and the Oxidative Gene Program#

When Cardarine binds PPARδ, the receptor heterodimerizes with RXR and translocates to the nucleus, where it upregulates the core fatty-acid oxidation machinery: CPT1b (shuttles long-chain fatty acids into mitochondria), UCP3, PDK4 (spares glucose by suppressing pyruvate dehydrogenase), and genes driving mitochondrial biogenesis. The net result is a muscle that preferentially burns fat for fuel at a given workload — which is exactly why steady-state cardio suddenly feels like cheating around week 2.

The AMPK Co-Signal — Why Training Matters#

The critical nuance, and the one most vendor pages get wrong, is that Cardarine is not a "sit on the couch and lose fat" drug. The full endurance transcriptome only expresses when PPARδ activation is paired with exercise-driven AMPK signalling. AMPK phosphorylates PPARδ and unlocks the downstream gene program; without training, you get partial lipid effects but none of the super-endurance phenotype.

"GW501516 treatment alone induced the expression of genes involved in fatty acid oxidation, but only exercise plus GW501516 produced the full endurance-exercise gene program and significantly increased running time and distance." — Narkar VA et al., Cell, 2008

Practical takeaway: dose 30–45 minutes pre-cardio or pre-lift, and actually do the cardio. The compound rewards volume.

Lipid Remodelling via Reverse Cholesterol Transport#

In the liver and peripheral tissues, PPARδ activation upregulates ABCA1, driving reverse cholesterol transport (HDL up), and shifts hepatic lipid handling toward oxidation rather than VLDL export (triglycerides and ApoB down). This is the mechanistic basis for the lipid signature seen in human trials and the reason Cardarine is so commonly stacked with harsh 17α-alkylated orals.

"Administration of GW501516 at 2.5 and 10 mg/day for 2 weeks reduced triglycerides by up to 30%, apolipoprotein B by 26%, LDL by 23%, and increased HDL by 15% in healthy subjects." — Sprecher DL et al., Arterioscler Thromb Vasc Biol, 2007

For anyone running anadrol, superdrol, or dbol and watching their HDL crater, this is the mechanism that makes Cardarine a standard lipid-rescue adjunct — it won't fully bail out a hammered panel, but it measurably softens the crash.

Substrate Partitioning and the "Recomp" Effect#

By biasing fuel selection toward free fatty acids, Cardarine effectively spares muscle glycogen during training and pushes stored adipose into circulation for oxidation. Users see this as better vascularity, flatter midsections in deficit, and meaningfully easier conditioning work. It does not build muscle — the muscle growth, strength, and anabolic rating scalars on this page are zero for a reason — but by reshaping substrate use, it lets you train harder and longer in a deficit without the usual performance collapse.

What It Does Not Do#

Worth stating plainly, because vendor marketing muddles this: Cardarine does not bind the androgen receptor, does not raise IGF-1, does not increase nitrogen retention, and does not add lean mass on its own. If you see weight-neutral or slightly-down scale movement with visible conditioning gains, the mechanism is working exactly as designed. Any lean-mass gain on a Cardarine cycle is coming from whatever else is in the stack — ostarine, MK-677, a test base — not from the PPARδ agonism itself.

Common (most users)#

• Mild headaches in week 1 — typically resolve as you adjust. Hydrate aggressively and take the dose with food if it persists past day 5.
• Mild insomnia if dosed late — move the dose to pre-workout or morning. The 16–24 h half-life means timing doesn't affect efficacy.
• Looser stools / mild GI at 20 mg — drop to 10–15 mg for a week, then titrate back up. Splitting into 10 mg AM / 10 mg pre-training usually fixes it.
• Transient fatigue in week 1 — the metabolic shift toward fatty-acid oxidation takes a few sessions to settle. Push through; by week 2 the opposite effect (noticeably easier cardio) takes over.

Uncommon (dose-dependent or individual)#

• Elevated liver enzymes — rare in short cycles but worth monitoring. Pull a CMP at baseline, week 4, and post-cycle. If ALT/AST drift above 2× the upper limit, stop and reassess — especially if you're stacking with 17α-alkylated orals.
• Unexpected lipid shifts — the population trend is HDL up and TG down, but individual responses vary. Week-4 bloodwork catches outliers.
• Subjective "wired" feeling at 20 mg — some users describe mild restlessness or a stimulant-like edge. Drop back to 15 mg; it's not a dose worth pushing past.
• Appetite suppression — usually welcome on a cut, but flag it if you're running a recomp and falling behind on calories.

Rare but serious#

• Carcinogenicity signal from chronic high-dose rodent data — this is the dominant long-term concern. Two-year rodent studies at high doses showed dose-related tumor increases across multiple tissues (liver, bladder, skin, stomach, others), which is why GSK/Ligand terminated development.

"Treatment with high doses of GW501516 in 2-year rodent carcinogenicity studies resulted in an increased incidence of multiple tumor types across several tissues." — Perreault et al., PPAR Research (2008)

No human cancer signal has been documented, but human trial data caps out around 12 weeks. The community response — which is sound — is to cap individual cycles at 8–12 weeks, limit cumulative annual exposure, and not run this year-round.

• Counterfeit / mis-labeled product harm — GW501516 is one of the most commonly substituted research chemicals on the market. Unverified product can contain anything. Buy only from vendors publishing third-party HPLC, and ideally send your own vial out for testing.

Hard contraindications#

• Active malignancy or personal history of cancer — do not run. The rodent data is unambiguous enough that this is a bright line.
• Pregnancy or lactation — do not run.
• Significant liver disease — skip it; use something with a cleaner hepatic signal.
• Tested athletes — WADA-banned year-round under S4.5, and detectable in hair for months.

"Hair analysis revealed that GW501516 and its metabolites can be detected for months following administration, underscoring its relevance for doping control and athlete testing." — Thevis et al., Drug Test Anal (2020)

Gender-specific and PCT considerations#

Cardarine is non-hormonal — it doesn't bind the androgen receptor, doesn't aromatize, and doesn't suppress the HPTA. No PCT is required, and women can run the same 10–20 mg/day dosing as men with zero virilization risk. The pregnancy/lactation exclusion above is the only female-specific caveat. For men stacking Cardarine with suppressive compounds (SARMs, AAS), PCT is driven entirely by those compounds, not by the GW itself.